Ascelia Pharma AB (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Ascelia Pharma AB

Ascelia Pharma is an oncology-dedicated orphan drug company listed on Nasdaq Stockholm under the ticker ACE.

Founded 2000 Sweden

Sweden 16 employees Post Ipo Equity Total: $200.00M Biotechnology, Health Care +1

Ascelia Pharma AB is a biotech company based in Sweden, specializing in orphan oncology treatments. The company is listed on Nasdaq Stockholm under the ticker ACE. As of March 17, 2021, it received a kr200.00MPost-IPO Equity investment from notable investors including Sunstone Capital, HealthInvest Partners, Oresund Healthcare Management, Fourth Swedish National Pension Fund, and Svenska Handelsbanken. Ascelia Pharma has two promising drug candidates in its pipeline. The first is Orviglance (formerly known as Mangoral), a novel oral contrast agent for MR-imaging designed to enhance the detection of focal liver lesions in patients with reduced kidney function. This drug has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA) and is currently in Phase 3 development, including the global multi-center SPARKLE study. The second candidate is Oncoral, a novel oral irinotecan tablet developed for the treatment of difficult-to-treat cancers, initially focusing on gastric cancer. This drug has shown promising results in Phase 1 clinical trials, and Phase 2 development is in preparation. Overall, Ascelia Pharma's innovative approach to addressing unmet medical needs in the oncology space, along with its strong investor support, positions the company as a significant player in the biotechnology and pharmaceutical industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	••••••	5	•••• ••••	17 Mar 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

••••••

•••• ••••

17 Mar 2021

FAQ About Ascelia Pharma AB

Ascelia Pharma is an oncology-dedicated orphan drug company listed on Nasdaq Stockholm under the ticker ACE.

Ascelia Pharma AB was founded in 2000.

Ascelia Pharma AB is headquartered in Sweden.

Ascelia Pharma AB operates in the following industries: Biotechnology, Health Care, Pharmaceutical.

Ascelia Pharma AB has approximately 16 employees.

Ascelia Pharma AB has completed 1 funding round, raising a total of $200.00M. The latest funding stage is Post Ipo Equity.

Top alternatives and competitors to Ascelia Pharma AB include Phanes Therapeutics, Inc., Inspirna, Inc., INVENT Pharmaceuticals, Entera Bio Ltd., Akanocure Pharmaceuticals, Inc. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Ascelia Pharma AB and Phanes Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Ascelia Pharma AB

General Information

Track Ascelia Pharma AB

Discover More

About Ascelia Pharma AB

Funding Rounds & Investors (1)

Ascelia Pharma AB Alternatives & Competitors

FAQ About Ascelia Pharma AB

Don't just browse. Track.